Synlogic

Synlogic is a biopharmaceutical company that brings innovative medicine to patients. The medicines are designed to treat disease by taking action from the microbiome to correct metabolic dysfunction. The two lead programs are in Urea Cycle Disease (UCD) and Phenylketonuria (PKU) and the company has a full pipeline of disorders which utilize their synthetic biotic platform.

Deerfield invested through Synlogic’s $40 million Series B financing which will be used to advance Synlogic’s pipeline and platform.